Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.28 USD
−34.03 M USD
2.05 M USD
5.62 M
About Lumos Pharma, Inc.
Sector
CEO
Richard J. Hawkins
Headquarters
Austin
Website
Founded
1999
FIGI
BBG001CDB921
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of LUMO is 4.30 USD — it has decreased by −0.23% in the past 24 hours. Watch Lumos Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lumos Pharma, Inc. stocks are traded under the ticker LUMO.
LUMO stock has fallen by −0.46% compared to the previous week, the month change is a −1.60% fall, over the last year Lumos Pharma, Inc. has showed a 38.71% increase.
We've gathered analysts' opinions on Lumos Pharma, Inc. future price: according to them, LUMO price has a max estimate of 4.25 USD and a min estimate of 4.25 USD. Watch LUMO chart and read a more detailed Lumos Pharma, Inc. stock forecast: see what analysts think of Lumos Pharma, Inc. and suggest that you do with its stocks.
LUMO reached its all-time high on Apr 9, 2015 with the price of 528.57 USD, and its all-time low was 1.37 USD and was reached on Jul 10, 2024. View more price dynamics on LUMO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LUMO stock is 0.93% volatile and has beta coefficient of 1.35. Track Lumos Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lumos Pharma, Inc. there?
Yes, you can track Lumos Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Lumos Pharma, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
LUMO net income for the last quarter is −7.47 M USD, while the quarter before that showed −7.55 M USD of net income which accounts for 1.11% change. Track more Lumos Pharma, Inc. financial stats to get the full picture.
No, LUMO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 33.00 employees. See our rating of the largest employees — is Lumos Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lumos Pharma, Inc. EBITDA is −36.31 M USD, and current EBITDA margin is −1.78 K%. See more stats in Lumos Pharma, Inc. financial statements.
Like other stocks, LUMO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lumos Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lumos Pharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lumos Pharma, Inc. stock shows the neutral signal. See more of Lumos Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.